7月1日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 【品大事】 新大陆：设立境外子公司并取得美国MSB牌照 新大陆(000997)公告，为加快支付全产业链的全球化布局，推进跨境支付业务的拓展，公司控股子 公司上海杉昊智能科技发展有限公司的全资子公司香港星驿支付有限公司出资1美元设立NovaPay US Inc.（简称"NovaPay"）。近日，公司获悉NovaPay已设立完成，取得公司注册证明书，并经 美国FinCEN批准授予MSB牌照。公司获取美国MSB牌照，旨在为开展跨境资金业务提供合法准入 资质，覆盖货币兑换、汇款、数字货币交易等场景，为对接全球主流金融机构提供基础设施，奠定跨 境支付相关业务开展的基础，助力公司全球化战略布局。 浙江黎明：实控人方面承诺1年内不减持公司股份 2025.07. 01 昂利康：公司目前在研创新药项目仅有一个 昂利康(002940)发布股票交易异动公告称，近期市场对创新药业务关注度较高，公司目前在研的创 新药项目仅有一个，系ALK-N001项目，该项目于2025年4月获得药物临床试验批准通知书，截至 目前，该项目尚处于I期临床试验 ...

7月1日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 【品大事】 新大陆：设立境外子公司并取得美国MSB牌照 新大陆(000997)公告，为加快支付全产业链的全球化布局，推进跨境支付业务的拓展，公司控股子公司 上海杉昊智能科技发展有限公司的全资子公司香港星驿支付有限公司出资1美元设立NovaPay US Inc. （简称"NovaPay"）。近日，公司获悉NovaPay已设立完成，取得公司注册证明书，并经美国FinCEN批 准授予MSB牌照。公司获取美国MSB牌照，旨在为开展跨境资金业务提供合法准入资质，覆盖货币兑 换、汇款、数字货币交易等场景，为对接全球主流金融机构提供基础设施，奠定跨境支付相关业务开展 的基础，助力公司全球化战略布局。 *ST元成(603388)公告，公司，公司控股股东、实控人祝昌人当日收到证监会《立案告知书》，因公司 涉嫌年报等定期报告财务数据虚假披露，证监会决定对公司，公司控股股东、实控人祝昌人立案。若后 续经证监会行政处罚认定的事实，触及重大违法强制退市情形，公司股票将被实施重大违法强制退市。 昂利康：公司目前在研创新药项目仅有一个 昂利康 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]